Statements (63)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:monoclonal_antibody
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Regen-Cov
gptkb:Regeneron |
| gptkbp:activities |
neutralizing antibodies
|
| gptkbp:appointed_by |
gptkb:hospital
hospital settings high-risk patients subcutaneous injection |
| gptkbp:approves |
gptkb:drug
|
| gptkbp:associated_with |
reduced mortality rates
|
| gptkbp:can_be_used_with |
other vaccines
other COVID-19 treatments |
| gptkbp:clinical_trial |
gptkb:Regeneron_Pharmaceuticals
Phase 3 |
| gptkbp:consists_of |
gptkb:casirivimab
gptkb:imdevimab |
| gptkbp:designated_as |
intravenous infusion
subcutaneous injection |
| gptkbp:developed_by |
gptkb:Regeneron_Pharmaceuticals
|
| gptkbp:emergency_services |
gptkb:FDA
|
| gptkbp:first_awarded |
November 2020
|
| https://www.w3.org/2000/01/rdf-schema#label |
REGEN-COV
|
| gptkbp:involves |
monoclonal antibody infusion
two monoclonal antibodies |
| gptkbp:is_a |
gptkb:vaccine
substitute for vaccination |
| gptkbp:is_aimed_at |
gptkb:SARS-Co_V-2
|
| gptkbp:is_available_in |
gptkb:various_countries
|
| gptkbp:is_available_on |
a treatment option
|
| gptkbp:is_considered |
a significant advancement in treatment options.
a therapeutic monoclonal antibody an important tool in managing COVID-19 |
| gptkbp:is_effective_against |
certain variants
COVID-19 progression all COVID-19 variants reducing viral load |
| gptkbp:is_evaluated_by |
ongoing studies
safety and efficacy variants of concern |
| gptkbp:is_part_of |
Regeneron's COVID-19 treatment portfolio
emergency response to COVID-19 therapeutic strategies for COVID-19 treatment guidelines for COVID-19 |
| gptkbp:is_studied_in |
various clinical trials
prophylactic use |
| gptkbp:is_used_for |
preventing severe COVID-19
COVID-19 patients |
| gptkbp:is_used_in |
emergency situations
clinical practice immunocompromised patients |
| gptkbp:marketed_as |
gptkb:REGEN-COV
|
| gptkbp:part_of |
COVID-19 response strategies
COVID-19 therapeutic options |
| gptkbp:reduces |
hospitalization rates
|
| gptkbp:requires |
medical supervision
|
| gptkbp:side_effect |
infusion reactions
|
| gptkbp:suitable_for |
health authorities
post-exposure prophylaxis mild to moderate COVID-19 without risk factors |
| gptkbp:treatment |
high-risk conditions
at high risk for severe disease |
| gptkbp:used_in |
outpatient settings
|